The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 44 results
Sort by date: Descending
Encores: Not included
Sleep-wake disorders
AAN 2026 POSTER
Improvement in Patient-Reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type 1 Treated With Alixorexton, an Orexin 2 Receptor Agonist, in the Vibrance-1 Phase 2 study
AUTHOR(S)

Yves Dauvilliers,1 Ronald R. Grunstein,2,3 Emmanuel Mignot,4 Gert J. Lammers,5,6 David T. Plante,7 Erik Buntinx,8 Rafael del Río Víllegas,9,10 Hailu Chen,11 Craig Hopkinson,11 Bhaskar Rege,11 Julie Himes,11 Michael J. Doane,11 Giuseppe Plazzi12,13

View poster
Sleep-wake disorders
Bipolar Disorder
Schizophrenia
AMCP 2026 POSTER
Acute Care Events and Treatment Patterns 12 Months After Initiating Olanzapine/Samidorphan: Subgroup Analyses of Patients With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Hemangi R. Panchmatia, MSc,1 Andrew J. Cutler, MD,2,3 Noah S. Webb, PhD,4 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,1 Hara E. Oyedeji, DNP, PMHNP-BC,5 Rakesh Jain, MD, MPH6

View poster
Bipolar Disorder
Schizophrenia
Schizophrenia
PCNPI 2026 POSTER
Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia
AUTHOR(S)

Peter J. Weiden, MD1; Jelena Kunovac, MD, MS2-4; Shifang Liu, PhD5; Daniel J. Kim, PhD5; James A. McGrory, PhD5

View poster
Schizophrenia
Schizophrenia
PCNPI 2026 POSTER
Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia
AUTHOR(S)

Peter J. Weiden, MD1; Jelena Kunovac, MD, MS2-4; Shifang Liu, PhD5; Daniel J. Kim, PhD5; James A. McGrory, PhD5

View poster
Schizophrenia
Schizophrenia
PCNPI 2026 POSTER
Use of an Aripiprazole Lauroxil Injection Administered Once Every Month, 6 Weeks, or 2 Months in People With Schizophrenia: A Clinician-Focused Summary of Study Data
AUTHOR(S)

Brooke Kempf, PMHNP-BC,1 Julie A. Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, FAAN,2 Rebecca Barbee, MSPAS, PA-C, CAQ-Psych,3 Andrew J. Cutler, MD,4,5 Craig Chepke, MD, DFAPA,6,7 Mark S. Todtenkopf, PhD,8 Daniel J. Kim, PhD,8 James A. McGrory, PhD,8 Dave McDonnell, MD,9 Peter J. Weiden, MD10

View poster
Schizophrenia
Bipolar Disorder
Schizophrenia
NEI 2025 POSTER
Trial in Progress: A Randomized, Double-Blind Trial Comparing OLZ/SAM vs Olanzapine in Pediatric Patients With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Lara Finlayson,1 April Wurnitsch,1 Alexandra Lovett,1 David McDonnell 2

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia